To recap, Pfizer and its German partner BioNTech announced last night that their experimental Covid-19 vaccine was more than 90% effective with no serious safety concerns based on initial trial results, estimating that they can roll out up to 50 million doses this year for 25 million people and produce 1.3 billion doses in 2021.
So. Takes time to finally put in the market and then distribute to customers.
Covid-19 vaccine dampens sentiment on glove counters in morning trade KUALA LUMPUR (Nov 16): Glove stocks were headed lower in Bursa Malaysia's morning trading session today due to the news flow of Covid-19 vaccine progress, which dampened sentiment on the counters. As at the time of writing, glove stocks were among the top losers today. At 11.53am, Hartalega Holdings Bhd, being the second top loser, was down 4.29% or 66 sen at RM14.72, bringing its market capitalisation lower to RM50.54 billion. It saw some 2.78 million shares traded. In the fourth place was Supermax Corp Bhd, which fell 5.24% or 46 sen to RM8.32, with a market value of RM22.72 billion. More than seven months after the World Health Organization (WHO) declared the Covid-19 outbreak in China a “public health emergency of international concern”, the global economy continues to reel from the impact of the virus. Meanwhile, Top Glove Corp Bhd, which bought back 8.94 million or 0.72% of its shares for RM69.9 million in the open market last Friday, dropped 3.98% or 31 sen to RM7.47, valuing the stock at RM61.47 billion. The counter was the seventh biggest loser as at the time of writing. The smaller players were also not spared from the selling pressure. Kossan Rubber Industries Bhd lost 4.2% or 28 sen to RM6.38, Careplus Group Bhd fell 6.58% or 20 sen to RM2.84, and Comfort Gloves Bhd shed 4.71% or 19 sen to RM3.84. The Healthcare Index was dragged down by the glove stocks, declining by 1.75% or 69.68 points to 3,921.47. Last week, Pfizer and its German partner BioNTech announced that their experimental Covid-19 vaccine was more than 90% effective with no serious safety concerns based on initial trial results. They also estimated that they can roll out up to 50 million doses this year for 25 million people and produce 1.3 billion doses in 2021.
Govt has communicated with 10 Covid-19 vaccine producers, says Khairy KUALA LUMPUR (Nov 16): The government has communicated with 10 Covid-19 vaccine producers following a notification by the World Health Organization (WHO) that there are 11 Covid-19 vaccine candidates in phase 3 clinical trial (as of Nov 13). Science, Technology and Innovation Minister Khairy Jamaluddin said communications with eight of the producers was made directly, while the other two was through the Covid-19 Vaccine Global Access Facility (COVAX). He said some of the discussions are in the final stage and an official announcement would be made when everything has been finalised. “The discussion covers aspects of cooperation in various stages of vaccine development such as R&D (research and development), exchange of scientists, fill and finish development (transfer of technology, logistics, cold chain), including the purchase of vaccines (finished products) as a guarantee of access to vaccine supply for the country," he said during the questions for oral answers session in the Dewan Rakyat today. He was responding to a question from Chan Foong Hin (Pakatan Harapan-Kota Kinabalu) who wanted to know whether the ministry had made any order to import vaccines from companies from China, such as Cansino, Sinovac and Sinopharm, or the UK, such as AstraZeneca, and whether the ministry would set the order of priority for Covid-19 vaccination as being done in Indonesia. Khairy said through participation in COVAX, Malaysia would have access to the supply of Covid-19 vaccine of 10% of the country's population and the government was working to get another 60% to meet the national immunisation target for herd immunity to up to 70 per cent of the country's population. The government, he said, was also working to get vaccine access as early as the first or second quarter of next year depending on the approval from the National Pharmaceutical Regulatory Agency (NPRA). He said the NPRA will ensure that a vaccine passes the stipulated strict conditions, covering its safety and effectiveness through data on the clinical trial that was conducted. Meanwhile, on the list of immunisation priorities, Khairy said the Special Committee on Covid-19 Vaccine Supply Access (JKJAV), set up on Oct 14 , had agreed to divide it into three groups, namely the frontliners, involving staff of the Ministry of Health (MoH) and agencies not under the MoH, such as the police, the Malaysian Armed Forces, Immigration Department and others, in the first group. The second is for high-risk groups, such as individuals with co-morbid and seniors citizens, and the third involves other adult population. Details of the groups are being made and the announcement is expected to be made during the first quarter of next year.
LKL won't die just because 215 topglov staff in Klang were confirmed covid-19 positive. At current price, LKL is certainly a good pick as there are many bed orders made by hospitals. Their staff are on overdrive....to cater the orders.
KUALA LUMPUR: TA Securities Research has lowered the target price of Top Glove Corporation from RM10.80 to RM8.84 as the workers dormitory and the surrounding area will be placed under an enhanced movement control order (EMCO) until Nov 30.
It said on Tuesday this lower TP was based on revised nine times CY21 EPS. The key risk is further extension of EMCO in the affected area where Top Glove’s plants are located, it added.
Just because announcement of vaccines doesn't mean that LKL or any health related companies will slump. Only retards think that way and run. Infections are even more on the rise and all Medical related service providers will require even more gloves and medical products. It will be even more than what was required since Mar this year. The ACTUAL, efficacy results have still not been provided by vaccine companies to their relevant governments for evaluation. All vaccine manufacturers will trumpet their findings so that they can announce they are the 1st and the best. Whether it really works without side effects is another thing altogether. I also can say I got one fantastic vaccine and works 100%, SHOW ME YOUR CLINICAL PAPERS and HOW IT WAS CONDUCTED, then I will say it works. OTHERWISE go jump in a lake.
yesterday KMM show added around 600 bed for KL hospital and sg buloh hospital... yes, this is only for these two hospital and we are talking about bed only...not yet included others hospital...and not yet included others item bought by kkm...
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
NPRA1985
3,415 posts
Posted by NPRA1985 > 2020-11-13 15:11 | Report Abuse
Moderna looks to first interim analysis in COVID-19 vaccine Phase 3 trial
https://www.biopharma-reporter.com/Article/2020/11/12/Moderna-looks-to-first-interim-analysis-in-COVID-19-vaccine-Phase-3-trial
-------------
Crucial Moderna Covid vaccine data is coming in days — here’s what to look out for
https://www.cnbc.com/2020/11/12/coronavirus-moderna-vaccine-data-is-coming-in-days-what-to-look-out-for.html